Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Allogeneic bone marrow transplantation.

P L Weiden

    Critical Reviews in Clinical Laboratory Sciences
    |January 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Allogeneic bone marrow transplantation offers a cure for severe aplastic anemia and acute leukemia. Despite challenges like graft rejection and infections, survival rates are improving, especially for leukemia patients treated early.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL).

    Critical reviews in oncology/hematology·2001
    Same author

    Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001
    Same author

    Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin.

    Cancer biotherapy & radiopharmaceuticals·2000
    Same author

    Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results.

    Cancer biotherapy & radiopharmaceuticals·2000
    Same author

    Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2000
    Same author

    Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin.

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2000
    Same journal

    Indirect methods for the verification of reference intervals in laboratory medicine.

    Critical reviews in clinical laboratory sciences·2026
    Same journal

    Sustainability and waste reduction in clinical laboratories.

    Critical reviews in clinical laboratory sciences·2026
    Same journal

    Aptamer-based biosensing strategies for influenza virus detection: a systematic and critical review of electrochemical and optical platforms.

    Critical reviews in clinical laboratory sciences·2026
    Same journal

    Advancing patient safety through laboratory quality indicators in clinical pathology.

    Critical reviews in clinical laboratory sciences·2026
    Same journal

    Blood biomarkers for the diagnosis of chorioamnionitis following preterm premature rupture of membranes: a systematic review and meta-analysis of studies since 2020.

    Critical reviews in clinical laboratory sciences·2026
    Same journal

    Single cell mechanodeformation signatures as early biomarkers for hematological malignancies.

    Critical reviews in clinical laboratory sciences·2026
    See all related articles

    Area of Science:

    • Hematology
    • Immunology
    • Oncology

    Background:

    • Allogeneic bone marrow transplantation (BMT) is a recognized treatment for severe aplastic anemia and acute leukemia.
    • Key challenges in BMT for aplastic anemia include graft rejection and graft-versus-host disease (GVHD).
    • For acute leukemia, complications include infections, leukemia recurrence, GVHD, and interstitial pneumonia.

    Purpose of the Study:

    • To review the established role and ongoing challenges of allogeneic bone marrow transplantation in treating severe aplastic anemia and acute leukemia.
    • To discuss advancements and persistent issues in managing complications such as graft rejection, GVHD, infections, and interstitial pneumonia.
    • To evaluate the current survival outcomes and potential for cure in patients undergoing BMT for these hematologic malignancies.

    Related Experiment Videos

    Main Methods:

    • Review of established clinical practices and outcomes in allogeneic bone marrow transplantation.
    • Analysis of strategies to mitigate complications like graft rejection and GVHD, including immunosuppressants (e.g., cyclosporine A) and irradiation.
    • Evaluation of methods to prevent infections (e.g., ultra-isolation, granulocyte transfusions) and manage leukemia recurrence.

    Main Results:

    • BMT outcomes are better in younger, non-transfused patients with aplastic anemia.
    • Early infections in leukemia patients are reduced by ultra-isolation and granulocyte transfusions.
    • Transplantation during first remission improves outcomes for acute non-lymphoblastic leukemia; 60% survival is achievable.
    • Relapsed leukemia patients show improved survival with BMT compared to chemotherapy, with potential for cure.

    Conclusions:

    • Allogeneic BMT provides a significant chance of cure for patients with severe aplastic anemia and acute leukemia, including relapsed cases.
    • Managing GVHD and interstitial pneumonia remains critical for improving BMT success rates.
    • Early transplantation in remission offers the best prognosis for acute leukemia patients.